ABCD Empagliflozin Audit

About the ABCD nationwide empagliflozin audit

With the launch of the empagliflozin audit in March 2017, ABCD was now auditing all three from new class of drugs for diabetes, the SGLT2 inhibitors. As with the ABCD GLP1-receptor agonist audits (exenatide, liraglutide and exenatide QW) that were ongoing at the time, it was felt that patients being treated with SGLT2 inhibitors in real clinical practice might be different from those in clinical trials and outcomes might also be different both in terms of safety and efficacy. As with the exenatide QW, dapagliflozin and canagliflozin audits, this audit is again being hosted on HSCN - the latest version of NHSnet. Access the on-line tool for the audit does require the user to be on HSCN – ie in an NHS hospital, GP surgery etc. The audit has a number of objectives.

Web-based audit tool on HSCN

The audit tool for the empagliflozin audit is very similar to that being used for the dapagliflozin and canagliflozin audits. This will make comparison between the data in the three audits and combining data for analysis of class an easy task. The tool is easy to use. Being on HSCN it has optimum security for patient identifiable data with regard to your own patients, but anonymises the data when it is utilised in the national audit. There are some special features with regard to the data export both for your own local analysis and for the nationwide analysis. The export now allows you to choose which data to download for analysis as well as providing all data. It also allows you to choose to download the data aggregated to 2 monthly, 3 monthly, 4 monthly or 6 monthly time points.  The tool has the facility to detect data from the same patient entered in two sites (eg hospital and primary care) and to merge the data when exported - see centres and sites below. As with the canagliflozin audit, to improve patient safety, Boehringer Ingelheim's pharmacovigilance team will be alerted automatically of any serious adverse events. This is in addition to the usual advice that adverse events occurring in the UK should be reported to the yellow card scheme: www.mhra.gov.uk/yellowcard.

Structure of the audit – centres and sites

For this audit the concept of centres and sites is utilised in the same way as in the exenatide QW, dapagliflozin and canagliflozin audits. Typically a centre might be an NHS Trust. Sites might be hospitals associated with that Trust, and/or health centres or GP surgeries in the local vicinity. If set up in this structure, designated leaders of the local audit would be given access to download the anonymised data of all the patients associated with the centre for more powerful local analysis of data involving higher numbers. Findings so made through such local analysis could be put forward for further testing on the full national dataset.

Non ABCD members

Non ABCD members are welcome to take part in the audit and will be given access to the on-line audit tool when they register for the audit.

Collect data on-line or via paper forms

The on-line audit tool is so easy to use that live data entry in clinic is a real option to be considered. Otherwise to facilitate data collection during clinics there are two paper forms which exactly match the data that can be entered into the audit tool. You can download and print these forms locally – see the links provided.

How to analyse your data - video